Fluvastatin in the Therapy of Acute Coronary Syndrome

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00171275

Enrollment

1000

Registered

2005-09-15

Start date

2003-11-30

Completion date

Unknown

Last updated

2010-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Disease, Myocardial Infarction

Keywords

Coronary disease, Myocardial infarction, Statins

Brief summary

This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs.

Interventions

DRUGFluvastatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Acute coronary syndrome * Adults, 18 years and older

Exclusion criteria

* History of lipid lowering therapy less than 30 days before index event * Pregnancy and nursing * Subject younger than 18 years Other inclusion and

Design outcomes

Primary

Measure	Time frame
Change from baseline in circulating markers of inflammation after 4 weeks and after 52 weeks	—

Secondary

Measure	Time frame
Occurrence of death, nonfatal myocardial infarction, cardiac arrest with resuscitation, recurrent symptomatic ischemia, and urgent revascularization after 4 weeks and after 52 weeks	—

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026